Press release
Gout Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | AstraZeneca, R-Pharm, Allena Pharma, JW Pharma
The Gout Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Gout Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gout Market.
Some of the key takeaways from the Gout Pipeline Report:
* Companies across the globe are diligently working toward developing novel Gout treatment therapies with a considerable amount of success over the years.
* Gout companies working in the treatment market are TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others, are developing therapies for the Gout treatment
* Emerging Gout therapies in the different phases of clinical trials are- TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others are expected to have a significant impact on the Gout market in the coming years.
* In February 2024, PK Med, a biotechnology company headquartered in France, has obtained clearance from the US Food and Drug Administration (FDA) to progress its injectable gout treatment, PKM-01, directly into Phase II clinical trials, bypassing Phase I studies. The Phase II trial will assess three different doses of PKM-01, a combination therapy consisting of controlled-release colchicine with ropivacaine, an anesthetic. This prospective, randomized study aims to determine the optimal dosage of the treatment for further advancement into Phase III trials.
* In March 2023, Selecta Biosciences, Inc. revealed favorable outcomes from the Phase 3 DISSOLVE I & II trials, comparing SEL-212 against a placebo. SEL-212 aims to address chronic refractory gout.
Gout Overview
An extremely painful type of inflammatory arthritis that is common is gout. Usually, it only affects one joint at a time, most commonly the big toe joint. Periods of increased symptom severity are referred to as flares, and periods with no symptoms are referred to as remission.
Get a Free Sample PDF Report to know more about Gout Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight [https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Gout Drugs Under Different Phases of Clinical Development Include:
* TJC-0434: TaiwanJ Pharmaceuticals
* NC-2700: Nippon Chemiphar
* Research Program: HemoShear Horizon Therapeutics plc
* NC-2500: Nippon Chemiphar
* PRX-115: Protalix BioTherapeutics
* HZN-457: Horizon Therapeutics plc
* AR-882: Arthrosi Therapeutics
* DYV700: Dyve Biosciences
* LC350189: LG Chem
* SHR-4640: Jiangsu Hengrui Medicine Co.
* SEL-212: Selecta Biosciences Inc
* D-0120 + Allopurinol: InventisBio Co., Ltd
* ALLN-346: Allena Pharmaceuticals
* Dapansutrile: Olatec Therapeutics LLC
* SAP001: Shanton Pharma Co., Ltd.
* Tigulixostat: LG Chem
Gout Route of Administration
Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
Gout Molecule Type
Gout Products have been categorized under various Molecule types, such as
* Protein
* Small interfering RNA
* Small molecule
* Product Type
Gout Pipeline Therapeutics Assessment
* Gout Assessment by Product Type
* Gout By Stage and Product Type
* Gout Assessment by Route of Administration
* Gout By Stage and Route of Administration
* Gout Assessment by Molecule Type
* Gout by Stage and Molecule Type
DelveInsight's Gout Report covers around 40+ products under different phases of clinical development like
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Further Gout product details are provided in the report. Download the Gout pipeline report to learn more about the emerging Gout therapies [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Gout Therapeutics Market include:
Key companies developing therapies for Gout are - Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, Allena Pharmaceuticals, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Nippon Chemiphar, Sinovent, Shenyang Sunshine Pharmaceutical, Rigel Pharmaceuticals, Chongqing Fochon Pharmaceutical, Alnylam Pharmaceuticals, Enzychem Lifesciences, Arrowhead Pharmaceuticals, Horizon Therapeutics, and others.
Gout Pipeline Analysis:
The Gout pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.
* Gout key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Gout drugs and therapies [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Gout Pipeline Market Drivers
* The rise in the prevalence of Gout, Novel urate-lowering agents are some of the important factors that are fueling the Gout Market.
Gout Pipeline Market Barriers
* However, gaps in the quality of care, lack of knowledge about guidelines and evidence based gout management, lack of novel therapies in Gout pipeline and other factors are creating obstacles in the Gout Market growth.
Scope of Gout Pipeline Drug Insight
* Coverage: Global
* Key Gout Companies: TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC, Shanton Pharma Co., Ltd., LG Chem, and others
* Key Gout Therapies: TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, and others
* Gout Therapeutic Assessment: Gout current marketed and Gout emerging therapies
* Gout Market Dynamics: Gout market drivers and Gout market barriers
Request for Sample PDF Report for Gout Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Gout Report Introduction
2. Gout Executive Summary
3. Gout Overview
4. Gout- Analytical Perspective In-depth Commercial Assessment
5. Gout Pipeline Therapeutics
6. Gout Late Stage Products (Phase II/III)
7. Gout Mid Stage Products (Phase II)
8. Gout Early Stage Products (Phase I)
9. Gout Preclinical Stage Products
10. Gout Therapeutics Assessment
11. Gout Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Gout Key Companies
14. Gout Key Products
15. Gout Unmet Needs
16 . Gout Market Drivers and Barriers
17. Gout Future Perspectives and Conclusion
18. Gout Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gout-pipeline-review-2024-updates-latest-fda-ema-and-pmda-approvals-novel-and-emerging-therapies-clinical-trials-and-treatment-outlook-astrazeneca-rpharm-allena-pharma-jw-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gout Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | AstraZeneca, R-Pharm, Allena Pharma, JW Pharma here
News-ID: 3462069 • Views: …
More Releases from ABNewswire
Exploring the Impact of U.S. Government Shutdown on the Global Markets - An Excl …
Image: https://www.abnewswire.com/upload/2025/11/6ab92174e3dc0ee6c1bfafc8e655cfb4.jpg
A shutdown of the U.S. federal government, when Congress fails to pass spending legislation and many agencies cease non-essential operations, poses a material risk to the economy. But when viewed through the lens of market history and global asset flows, the evidence suggests that such shutdowns are often absorbed by the markets and, in several ways, may present tactical opportunities for globally diversified investors.
1. What a U.S. Government Shutdown…
Green Ammonia Market size growing at CAGR of 82.47% by 2030 | Rising Fertilizer …
The latest research by Mordor Intelligence covers the "Green Ammonia Market," delivering insights into market dynamics, drivers of growth, and long-term forecasts.
Green Ammonia Market Overview:
The global green ammonia market is expanding steadily as countries accelerate the shift toward low-carbon fertilizer, marine fuel, power generation, and hydrogen transport solutions. The green ammonia market [https://www.mordorintelligence.com/industry-reports/green-ammonia-market?utm_source=abnewswire] size is expected to grow from 0.27 million tons in 2025 to 5.41 million tons by 2030,…
Point of Care Diagnostics Market to Reach USD 84.93 Billion by 2030, Driven by R …
Mordor Intelligence has published a new report on Point Of Care Diagnostics Market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
The Point Of Care Diagnostics Market [https://www.mordorintelligence.com/industry-reports/point-of-care-diagnostics?utm_source=abnewswire] size is estimated at USD 53.63 billion in 2025, and is expected to reach USD 84.93 billion by 2030, at a CAGR of 9.63% during the forecast period (2025-2030). The market's growth is fueled by the increasing need for rapid,…
Enteral Feeding Devices Market Forecast to Reach USD 4.94 Billion by 2030, Drive …
Mordor Intelligence has published a new report on enteral feeding devices market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
The enteral feeding devices market [https://www.mordorintelligence.com/industry-reports/enteral-feeding-devices-market?utm_source=abnewswire] is projected to grow from approximately USD 3.72 billion in 2025 to USD 4.94 billion by 2030, according to a recent report by Mordor Intelligence. The growth reflects a compound annual growth rate (CAGR) of around 5.84 percent, driven primarily by technological…
More Releases for Gout
Chronic Gout Market Trends, Therapeutics, and Growth Opportunities
Chronic gout is a progressive form of arthritis characterized by elevated uric acid levels, leading to severe joint pain, inflammation, and long-term joint damage. This condition affects millions worldwide, often resulting in impaired mobility and reduced quality of life. With rising prevalence due to lifestyle changes, aging populations, and dietary habits, the Chronic Gout market is witnessing a surge in demand for advanced therapeutics, early diagnostics, and patient management solutions.
Download…
Chronic Gout Market Massive Growth opportunity Ahead
Introduction
Chronic gout is a form of arthritis characterized by recurrent attacks of severe pain, swelling, and inflammation in the joints, often due to the accumulation of uric acid crystals. This condition typically affects the big toe but can also impact other joints, including the knees, elbows, and wrists. Uric acid, a by-product of purine metabolism, accumulates in the body due to overproduction or underexcretion by the kidneys, leading to hyperuricemia…
Gout Market Innovations in Pain Management and Treatment
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Gout Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many…
Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory …
Report Summary
The global gout therapeutics market was valued at USD 2.78 Billion in 2021 and is expected to grow at a CAGR of 13.7% during the forecast period 2023-2032.
Gout Therapeutics Market Introduction
The deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues results in gout, an inflammatory arthritic disease. Gout is a typical type of painful inflammatory arthritis. One joint is typically affected at a time (often…
Global Gout Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Gout Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Gout Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/371311/gout-drugs
Market…
Gout Therapeutics Market Emerging Trends And Forecast By 2025
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Patients with multiple episodes of severe gout attacks every year or with…
